Replies to post #214079 on Innovation Pharmaceuticals Inc (IPIX)

[Amatuer17]

So this update was on Mar’17 - nearly 1 year back.

Important to note 2 points
1. “ with FDA permission, is to next proceed with a Phase 1 clinical trial in healthy volunteers using the oral route. “

2. Half life of oral dose - 1 hour

Point 1 means - K is going back to ground zero with oral - phase 1 and not even 1a - healthy volunteers - then P1a with sick patients then P2 for dose optimization and efficacy and then P3.

This means all efforts for last 4-5 years established that K is non-toxic and more like water and cannot be used as a effective drug

All this after oral formulation is completed and available.
Co has not given any update on oral formulation progress.

Good luck with K - wait for another 3 years to go to P2

2. Oral half life 1 hour - it is so short that to reach therapeutic level for any cancer they will have to give high dosage such as 500 mg - 2 tablets every 2 hours and this can bring side effects
In the end patient will eat K tablets as breakfast lunch and dinner no other food.